SEC Form 4 · accession 0001209191-18-044804

Atara Biotherapeutics, Inc. · ATRA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Tech. Operations Officer

Period of report

Aug 1, 2018

Accepted (ET)

Aug 1, 2018 · 6:21 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001604464

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Aug 1, 2018	M	1,500	$20.40	A	33,358	D
Common Stock^F2	Aug 1, 2018	S	1,000	$37.09	D	32,358	D
Common Stock	Aug 1, 2018	S	100	$37.65	D	32,258	D
Common Stock^F3	Aug 1, 2018	S	300	$39.05	D	31,958	D
Common Stock	Aug 1, 2018	S	100	$40.40	D	31,858	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F4	$20.40	Aug 1, 2018	M	1,500	D	—	Apr 3, 2024	Common Stock	1,500	78,500	D

F1Transaction pursuant to Rule 10b5-1 Plan adopted May 29, 2018.
F2The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.50 to $37.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.70 to $39.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F425% of the shares shall vest one year from April 3, 2017, and the remaining shares shall vest in 36 equal monthly installment thereafter, subject to the reporting person's continuous service.